Maze Therapeutics, Inc.
MAZE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001842295
In the last 90 days, Maze Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 161 institutions reported holding it in 13F filings for Q2 2026, worth $1.75B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Market capClose on Nov 10, 2026
- $1.94B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $6.23M in total
- 14
- 13F holdersQ2 2026, −1 vs. previous quarter
- 161
- 13F valueReported value at the end of Q2 2026
- $1.75B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$131.1M
- No comparable prior period
- Free cash flow, FY2025
- -$112.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 6.68M
- Shares sold short
- Change
- −843.3K
- −11.2% vs. previous
- Days to cover
- 8.76
- At average daily volume
Superinvestors holding MAZE, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Maze Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
1.3%
Maze Therapeutics, Inc.'s share of the portfolio
- Shares
- 366,028
- Value
- $10.9M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Maze Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)4:13 PM ET | Nov 2 | 2 days | Coloma Jason VChief Executive Officer | SSale | −34.5K | $30.25 | −$1.04M | −15.6%186.9K after | 4 lots10b5-1 |
| Oct 30, 2026 (view filing)4:14 PM ET | Oct 29 | 1 day | Dandekar AtulCSBO | SSale | −7.50K | $32.07 | −$240.5K | −18.8%32.3K after | 10b5-1 |
| Oct 2, 2026 (view filing)4:12 PM ET | Oct 1 | 1 day | Coloma Jason VChief Executive Officer | SSale | −34.5K | $27.02 | −$932.3K | −15.3%191.4K after | 2 lots10b5-1 |
| Oct 2, 2026 (view filing)4:09 PM ET | Oct 1 | 1 day | Bernstein HaroldPresident, R&D & CMO | SSale | −16.1K | $26.93 | −$434.7K | −100.0%0 after | 10b5-1 |
| Oct 1, 2026 (view filing)4:06 PM ET | Sep 29 | 2 days | Dandekar AtulCSBO | SSale | −7.50K | $27.06 | −$202.9K | −18.8%32.3K after | 10b5-1 |
| Sep 8, 2026 (view filing)4:20 PM ET | Sep 4 | 4 days | Bernstein HaroldPresident, R&D & CMO | SSale | −9.71K | $26.22 | −$254.5K | −100.0%0 after | 10b5-1 |
| Sep 4, 2026 (view filing)4:27 PM ET | Sep 2-3 | 2 days | Courtney PhillipsGC and Corp. Secretary | SSale | −3.99K | $26.24 | −$104.8K | −36.3%7.01K after | 4 lots |
| Sep 4, 2026 (view filing)4:25 PM ET | Sep 2-3 | 2 days | Dandekar AtulCSBO | SSale | −6.43K | $26.24 | −$168.8K | −16.6%32.3K after | 4 lots |
| Sep 4, 2026 (view filing)4:24 PM ET | Sep 2-3 | 2 days | Coloma Jason VChief Executive Officer | SSale | −22.6K | $26.24 | −$594.0K | −45.3%27.4K after | 4 lots |
| Sep 4, 2026 (view filing)4:22 PM ET | Sep 2-3 | 2 days | Bernstein HaroldPresident, R&D & CMO | SSale | −10.3K | $26.24 | −$270.1K | −51.5%9.71K after | 4 lots |
Top 10 13F holders, Q2 2026
See all 161 holdersThe largest institutional positions in Maze Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,032,915 | $150.2M | 3.27% | +465,641+10.2% | Added |
| TRV GP IV, LLC | 4,473,958 | $133.5M | 52.63% | 00.0% | Unchanged |
| ARCH Venture Management, LLC | 4,120,053 | $123.0M | 11.18% | 00.0% | Unchanged |
| Deep Track Capital, LP | 3,732,569 | $111.4M | 1.64% | +255,007+7.3% | Added |
| BlackRock, Inc. | 3,502,841 | $104.5M | 0.00% | +932,416+36.3% | Added |
| Jupiter Topco LLC | 3,408,045 | $101.8M | 0.04% | +3,408,045 | New |
| T. Rowe Price Investment Management, Inc. | 2,603,682 | $77.7M | 0.05% | +2,603,682 | New |
| Logos Global Management LP | 1,935,000 | $57.7M | 2.49% | +700,000+56.7% | Added |
| Vanguard Capital Management LLC | 1,778,222 | $53.1M | 0.00% | +342,566+23.9% | Added |
| AH Capital Management, L.L.C. | 1,702,225 | $50.8M | 0.36% | 00.0% | Unchanged |
Holders of 5% or more of MAZE
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Maze Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | 13G | 9.40%4.12M shares | New | May 15, 20251 filing | May 15, 2025 | SEC |
| Third Rock Ventures IV, L.P. | 13G/A | 9.30%4.47M shares | −4.60 ppfrom 13.90% | May 9, 20252 filings | Feb 13, 2026 | SEC |
| Deep Track Capital, LP | 13G/A | 9.02%3.95M shares | +2.11 ppfrom 6.91% | Feb 7, 20252 filings | Aug 14, 2025 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 9.00%4.34M shares | +1.30 ppfrom 7.70% | Feb 10, 20255 filings | Feb 13, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 5.80%2.86M shares | −1.50 ppfrom 7.30% | May 14, 20254 filings | May 15, 2026 | SEC |